Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial

Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial

Background Secukinumab has demonstrated sustained long‐term efficacy with a favourable safety profile in various psoriatic disease manifestations in adults. Objectives Here, the efficacy and safety of two secukinumab dosing regimens [low dose (LD) and high dose (HD)] in paediatric patients with seve...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the European Academy of Dermatology and Venereology 2021-04, Vol.35 (4), p.938-947
Hauptverfasser: Bodemer, C., Kaszuba, A., Kingo, K., Tsianakas, A., Morita, A., Rivas, E., Papanastasiou, P., Keefe, D., Patekar, M., Charef, P., Zhang, L., Cafoncelli, S., Papavassilis, C.
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal, Humanized
Child
Double-Blind Method
Humans
Original
Psoriasis
Psoriasis - drug therapy
Severity of Illness Index
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Secukinumab has demonstrated sustained long‐term efficacy with a favourable safety profile in various psoriatic disease manifestations in adults. Objectives Here, the efficacy and safety of two secukinumab dosing regimens [low dose (LD) and high dose (HD)] in paediatric patients with severe chronic plaque psoriasis over one year are reported. Methods In this multicentre, double‐blind study (NCT02471144), patients aged 6 to
ISSN:0926-9959
1468-3083
DOI:10.1111/jdv.17002